Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-760 · 3 trials · 3 indications
Investigator-assessed progression-free survival (PFS) Efficacy is evaluated using the Lugano Efficacy Evaluation Criteria for Malignant Lymphoma (Cheson 2014). PFS is defined as the time from randomization to PD or death due to any cause, whichever occurs first.
Tumor assessment data will continue to be collected. Tumor assessment data collected after end of treatment (EOT) will be used. Tumor assessment data collected during the study and after EOT will be included in the PFS analysis (treatment policy strategy).
Use of other systemic antitumor therapy before PD or death (in the absence of PD):Tumor assessment after use of other systemic antitumor therapy will not be included in the analysis. For patients using other anti-tumor therapy before PD or death (in absence of PD), PFS will be censored at the last evaluable tumor assessment before the use of other systematic anti-tumor therapy (hypothetical strategy).
OS is defined as the time from randomization to death due to any cause.
OS data will continue to be collected after the other systematic anti-tumor therapy, and the OS data collected before and after other systematic anti-tumor therapy will be included in analysis (treatment policy strategy).
OS data will continue to be collected after the patient's premature withdrawal from study treatment, and the OS data collected during the study treatment and after EOT will be included in analysis (treatment policy strategy).
Area under the plasma concentration-time curve from time zero to the last time point t where the concentration could be accurately determined
Area under the plasma concentration-time curve from time 0 to infinity
Maximum plasma concentration
| Arm | Type | Description |
|---|---|---|
| The experimental group | EXPERIMENTAL | Patients will receive HMPL-760 once daily (QD) orally in combination with R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
| The control group | PLACEBO_COMPARATOR | Placebo QD at the same dose as HMPL-760 in the experimental group will be given in the control group, and the combination therapy is the same as in the experimental group. |
| Treatment A | EXPERIMENTAL | All participants in treatment A will fast overnight for at least 10 hours prior to HMPL-760 dosing. |
| Treatment B | EXPERIMENTAL | All participants in treatment B will receive a standardized high-fat meal approximately 30 minutes before HMPL-760 administration |
| Treatment C | EXPERIMENTAL | All participants in treatment C will receive a standardized low-fat meal approximately 30 minutes before HMPL-760 administration |
| Treatment D | EXPERIMENTAL | All participants receive rabeprazole 20 mg orally QD 1 h before the breakfast on Day 15 and the morning of Day 16 to Day 20. Rabeprazole and HMPL-760 are orally administered concomitantly under fasted conditions on the morning of Day 21. |
| Name | Type | Description |
|---|---|---|
| HMPL-760 | DRUG | Patients will receive HMPL-760 once daily (QD) orally. |
| HMPL-760 Placebo | DRUG | Patients will receive HMPL-760 placebo once daily (QD) orally. |
| R-GemOx | DRUG | R-GemOx regimen in 21-day cycles for a total of 8 cycles. Rituximab 375 mg/m2 IV is given on Day 1 of each cycle, and gemcitabine 1000 mg/m2 IV followed by oxaliplatin 100 mg/m2 IV is given on Day 2 of each cycle. |
| Rabeprazole and HMPL-760 | DRUG | 20 mg of rabeprazole will be administered orally once daily in the morning from Day 15 to Day 21, and a 300 mg oral dose of HMPL-760 will be administered concomitantly with rabeprazole on Day21. |
Inclusion Criteria: 1. Sign the ICF and be able to follow the requirements of study protocol; 2. Age ≥18 years; 3. ECOG performance status score between 0 and 2; 4. Histopathologically confirmed diagnosis of DLBCL; 5. The investigator judges that the patient's current condition requires further tre...
HMPL-760 is an investigational small molecule being developed for B-Cell Non-Hodgkin's Lymphoma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma. It is also being studied in healthy participants for pharmacokinetic research. The drug is in clinical development and is not approved for any indication.
HMPL-760 targets BTK, a kinase involved in B-cell receptor signaling. By inhibiting BTK, the drug is designed to interfere with the survival and proliferation of malignant B-cells, which is relevant to its development in B-Cell Non-Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma.
HMPL-760 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM. The company is conducting clinical trials for this investigational BTK inhibitor in oncology indications.
HMPL-760 is in Phase 1 clinical development, with an additional Phase 3 trial currently recruiting. The Phase 1 studies are completed or not yet recruiting, while the Phase 3 study is actively enrolling patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma in China.
HMPL-760 is being studied in three clinical trials. NCT05190068 is a completed Phase 1 study in B-Cell Non-Hodgkin's Lymphoma. NCT07409428 is a recruiting Phase 3 trial combining HMPL-760 with R-GemOx in Relapsed/Refractory DLBCL. NCT07643272 is a not yet recruiting Phase 1 study in healthy participants.
HMPL-760 is not FDA approved. It is an investigational drug currently in clinical trials, including a Phase 3 study for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. The drug has not completed the regulatory approval process and remains under clinical investigation.